Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition
about
Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disordersEpstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2.Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples.Tofacitinab in renal transplantation.Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic MechanismThe Cellular Localization of Human Cytomegalovirus Glycoprotein Expression Greatly Influences the Frequency and Functional Phenotype of Specific CD4+ T Cell Responses.Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3Genome-wide analysis of Epstein-Barr virus (EBV) isolated from EBV-associated gastric carcinoma (EBVaGC).Identification and Characterization of Epstein-Barr Virus Genomes in Lung Carcinoma Biopsy Samples by Next-Generation Sequencing TechnologyAssociation of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers.CD4+ and CD8+ T-cell responses to latent antigen EBNA-1 and lytic antigen BZLF-1 during persistent lymphocryptovirus infection of rhesus macaquesEpstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing.Cytotoxic CD4 T Cells-Friend or Foe during Viral Infection?Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells.Herpesviruses placating the unwilling host: manipulation of the MHC class II antigen presentation pathway.Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options.Enhanced Detection of Antigen-Specific CD4+ T Cells Using Altered Peptide Flanking Residue Peptide-MHC Class II Multimers.Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.Repression of CIITA by the Epstein-Barr virus transcription factor Zta is independent of its dimerization and DNA binding.CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response.CD4 T cells specific for a latency-associated γ-herpesvirus epitope are polyfunctional and cytotoxic.Age-associated Epstein-Barr virus-specific T cell responses in seropositive healthy adults.Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay.Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses.Semaphorin 7A protein variants differentially regulate T-cell activity.
P2860
Q33650689-091D8349-8856-42A2-8D21-171581EAB464Q34116845-670A6546-7F6D-4C9D-BCC5-108C70A107A6Q34262322-E1BC0235-5026-4934-B432-26E769904C47Q34357184-6D686434-419B-48C2-A80E-D66F0549A9B6Q35994831-74AB0B31-7C02-45F9-8C9A-F542D425ACF0Q36075279-BE65150F-FB85-49E9-BA6C-F68872D249ADQ36116754-DC6A4EF6-600F-467B-8923-C72DE0535418Q36155542-6CEA53D6-E8C8-409A-8B06-4FD961C5C9CDQ36782621-2E08F60F-2B8A-41F2-92DD-C4337E2BB35DQ36910371-749A64E4-4A9D-4C96-8A48-7ED3513E646DQ36991772-7F58C281-FDEA-4052-8CB6-AB3B2EAAC9B6Q37036688-FDD646DE-9F78-4E57-8E73-4367C4892B1DQ37272108-BDAC83B1-0EED-4554-B62E-84DD02AF6FD0Q37597931-00519D1C-EF0A-4E2C-89B0-804B0735E2DCQ37667998-C39FF28F-2D9F-408C-84DB-68B8CF5C478CQ38046606-06137C34-146A-4916-9706-96E5641F5595Q38720593-CD7CC6DB-F71D-4AB5-B9A6-BBAE4B69A110Q38820674-60369153-C493-4513-9903-09E82FC01FD8Q39170011-C9189614-5A0B-457E-802C-37EDD92BF688Q39219487-53316EE7-35D9-4595-A914-04087B697415Q40471906-8340DB06-D70B-449E-B91E-69F260DC1CAFQ40876736-65896D8B-8CD8-4780-A813-4570AAE8A191Q41591290-D69A57F9-F0C2-4963-9B82-5B87B21F38D8Q41672415-D5CB0DC4-35BE-4B9C-90C1-578D0186DC04Q42229225-C9F9EE83-A5B8-405D-8AB9-D40AF51FB045Q43589817-2AD93DB9-43C8-40C7-A72C-7062B07ADD4FQ47195330-1DA7C68F-F708-450C-930C-8EF766AF26FCQ47325678-5BE3BEB7-95B9-40B1-B335-449555BF7ECF
P2860
Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Cytotoxic CD4+ T cell response ...... and in lytic cycle recognition
@en
Cytotoxic CD4+ T cell response ...... and in lytic cycle recognition
@nl
type
label
Cytotoxic CD4+ T cell response ...... and in lytic cycle recognition
@en
Cytotoxic CD4+ T cell response ...... and in lytic cycle recognition
@nl
prefLabel
Cytotoxic CD4+ T cell response ...... and in lytic cycle recognition
@en
Cytotoxic CD4+ T cell response ...... and in lytic cycle recognition
@nl
P2093
P2860
P356
P1476
Cytotoxic CD4+ T cell response ...... and in lytic cycle recognition
@en
P2093
Alan B Rickinson
Alison M Leese
Claire Shannon-Lowe
Heather M Long
Jared Quarcoopome
Laura L Quinn
Shawn R Connerty
P2860
P304
P356
10.4049/JIMMUNOL.1100590
P407
P577
2011-05-27T00:00:00Z